ArthroCare Corp. PT Raised to $47.00 (ARTC)
Jefferies Group hoisted their price target on shares of ArthroCare Corp. (NASDAQ:ARTC) from $38.00 to $47.00 in a research note issued on Wednesday, Analyst Ratings Net reports. Jefferies Group’s price target indicates a potential upside of 0.92% from the stock’s previous close.
ArthroCare Corp. (NASDAQ:ARTC) traded up 14.76% on Wednesday, hitting $46.57. The stock had a trading volume of 1,466,752 shares. ArthroCare Corp. has a 52-week low of $31.56 and a 52-week high of $49.95. The stock’s 50-day moving average is $38.77 and its 200-day moving average is $36.13. The company has a market cap of $1.322 billion and a P/E ratio of 64.11.
ArthroCare Corp. (NASDAQ:ARTC) last released its earnings data on Wednesday, October 30th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.27. The company had revenue of $91.86 million for the quarter, compared to the consensus estimate of $88.99 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. On average, analysts predict that ArthroCare Corp. will post $1.44 earnings per share for the current fiscal year.
In other ArthroCare Corp. news, SVP Bruce Prothro sold 6,167 shares of the stock on the open market in a transaction dated Monday, January 6th. The stock was sold at an average price of $39.75, for a total transaction of $245,138.25. Following the completion of the transaction, the senior vice president now directly owns 39,421 shares in the company, valued at approximately $1,566,985. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
ARTC has been the subject of a number of other recent research reports. Analysts at Piper Jaffray raised their price target on shares of ArthroCare Corp. from $43.00 to $46.00 in a research note to investors on Friday, November 1st. They now have an “overweight” rating on the stock. Analysts at Canaccord Genuity raised their price target on shares of ArthroCare Corp. from $45.00 to $48.00 in a research note to investors on Thursday, October 31st. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. ArthroCare Corp. currently has a consensus rating of “Buy” and an average price target of $49.67.
ArthroCare Corporation (NASDAQ:ARTC), is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.